Open Label Trial of NanoDOX Hydrogel in Orthopedic Trauma Wounds With and Without Vacuum Assisted Closure Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effect of NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on the healing rates of open traumatic orthopedic and soft tissue wounds when compared to a serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

NCT00764361

Diabetic Foot Ulcer

COMPLETED PHASE2

Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer

NCT06667752

Diabetic Foot Ulcer Diabetic Foot Infection

RECRUITING NA

Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-healing Wound Management: A Phase II Trial

NCT01784887

Non-healing Soft Tissue Wounds

TERMINATED PHASE1/PHASE2

Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot

NCT00224796

Diabetic Foot

COMPLETED PHASE4

Trial of Negative-pressure Wound Therapy Use in Conflict-related Extremity Wounds

NCT02444598

Wounds, Gunshot Arm Injuries Leg Injuries +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Orthopedic Trauma Wounds

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NanoDOX Hydrogel plus VAC

NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.

Group Type EXPERIMENTAL

NanoDOX Hydrogel

Intervention Type DRUG

NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy

VAC Alone

Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.

Group Type ACTIVE_COMPARATOR

VAC Alone

Intervention Type OTHER

Patients will receive VAC therapy three time weekly for eight weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NanoDOX Hydrogel

NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy

Intervention Type DRUG

VAC Alone

Patients will receive VAC therapy three time weekly for eight weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be 18 years of age or older
* Women of childbearing potential must have a negative urine pregnancy test at screening and at baseline
* Agree to use a double-barrier method of contraception during their participation in this study

* condoms (with spermicide) and hormonal contraceptives OR
* condoms (with spermicide) and intrauterine device OR
* intrauterine device and hormonal contraceptives OR
* Abstains from sexual intercourse during their participation in this study
* Is with a same-sex partner and does not participate in bisexual activities where there is a risk of becoming pregnant
* Have a full-thickness trauma wound that is between 1.2cm2 and 24cm2 at initial screening
* Be able to apply study drug to their wound, or have a reliable and capable caregiver do it
* Subjects will have adequate blood flow to the wound as defined by transcutaneous oxygen tension (TcpO2) of \>30mmHg recorded over intact epidermis at the wound margin.

Exclusion Criteria

* Less than 18 years of age
* Pregnant or lactating woman or a female of childbearing potential who is not practicing acceptable form of birth control.
* Allergic to tetracycline, minocycline, demeclocycline, or any other known tetracycline derivative
* Tested positive for a doxycycline-resistant infection
* Have undergone treatment with systemic corticosteroid or immunosuppressive therapy in the past 2 months
* Currently undergoing dialysis for renal failure
* Have participated in another clinical research trial within the last 30 days
* Subject has wounds resulting from any cause other than trauma (diabetes, electrical burn, arterial insufficiency, chemical or radiation insult)
* Active or previous (within 60 days prior to the study screening visit) chemotherapy
* Active or previous (within 60 days prior to the study screening visit) radiation to the affected wound area to be treated by investigational drug or placebo
* Physical or mental disability or geographical concerns (residence not within reasonable travel distance) that would hamper compliance with required study visits
* The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including the shock wave treatment procedure, standard-of-care self-care requirements, and all study-related follow up visit requirements.
* History of sickle cell anemia
* History of infection with Human Immunodeficiency Virus
* History of other immunodeficiency disorders
* Severe anemia - Hgb \< 7 g/dl (males) or \< 6.5 (females)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No